Anavex Life Sciences Corp (AVXL)

[sokol]

Alzheimer’s Trial - Open Label Extension Note: Missling says that conversion from the placebo controlled part of the AD clinical trial to open label is very high, which is a good sign. Currently, the conversion rate from the placebo to AVXL 2-73 is above 94% at the request of the patient, the caretaker for the patient and the physician for the patient. See below quote from the transcript of yesterday’s conference call:

“So we have an extension study called Attention ID, which is a two year study of following up as an open label after the 48 week, which has started, after the first patient finished the 48 weeks. And because these patients have actually, some of them finished this phase two open label extension, they had requested to continue to stay on the study drug.

And so what we did, we initiated and we're successful in expanding now this attention AB study open label extension from two years to three years. So patients who are finish the study, the placebo control study, enter into the extension study finish the two years will now continue to go into the third year. And that is because of request by the patient, the caretakers and the physician. It also, I like to add that the I like to add also that the conversion from the placebo controlled part of the study to the open label is very high it's above 94% currently, which is a good sign.”